Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MyMy: MYREPTIC-N vs MY-REPT in Kidney Transplant Recipients
NCT06044493Phase 4Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate sodium in kidney transplant rejection (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Incidence of composite efficacy failure at 24 weeks. Started Nov 2023; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT06044493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06044493.